CURRENT REPORT 39/2023
August 4, 2023

Conclusion of two agreements in the area of operational execution of RVU120 Phase II clinical trials in hematology

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow, Poland ("Company", "Ryvu") informs that on August 4, 2023, two agreements were concluded with Fortrea Inc., headquartered in North Carolina, US ("Fortrea", formerly known as LabCorp Drug Development Inc.), covering operational execution of the RIVER-52 ("Agreement 1") and the RIVER-81 ("Agreement 2") clinical trials (jointly the "Agreements"). The conclusion of the Agreements serves the implementation of the goals indicated in the "Development Plans for 2022-2024" ("Development Plans"), as announced by the Company in the current report 16/2022 on August 19, 2022.

Agreement 1: The subject of Agreement 1 is the operational execution of the RIVER-52 clinical study – a global, multicenter, Phase II study of RVU120 as monotherapy in the treatment of patients with Acute Myeloid Leukemia/High-Risk Myelodysplastic Syndrome (AML/HR-MDS). The total value of Agreement 1 will amount up to approximately EUR 10.9 million, including all the investigators and clinical sites-related fees for the study procedures. The Company's Management Board assumes a possible fast-to-market strategy for the RIVER-52 study, with a potential initiation of the drug registration process in 2025.

Agreement 2: The subject of Agreement 2 is to operationally execute the RIVER-81 clinical study – a global, multicenter, Phase II study that will evaluate the safety and efficacy of RVU120 in combination with venetoclax in patients with relapsed/refractory AML, who have failed prior therapy with venetoclax and a hypomethylating agent. The total value of Agreement 2 will amount up to approximately EUR 11.5 million, including all the investigators and clinical sites-related fees for the study procedures. The costs associated with the implementation of the Agreement 2 will be co-financed by the Medical Research Agency ("ABM") from the state budget, in the framework of a competition for the development of targeted or personalized medicine based on nucleic acid therapy or small-molecule compounds, in which the Company has been selected as one of the beneficiaries and proceeded to enter into financing agreement with ABM, as informed in the current report no. 38/2023 on July 31, 2023.

Services under the Agreements will cover operational execution of the clinical studies, including but not limited to clinical project management, medical and safety monitoring, as well as clinical sites management and monitoring.

Depending on the observed clinical activity of RVU120, the total enrollment in both studies under the Agreements could reach up to approximately 230 patients, with enrollment taking place in up to approximately 90 clinical sites, in up to eight countries worldwide. Fortrea will provide continuous support in all the locations of the study conduct.

In the opinion of the Company's Management Board, the conclusion of Agreements with Fortrea represents the completion of a series of key contracts regarding the implementation of RVU120 Phase II clinical trials in hematology: RIVER-52 and RIVER-81, as reported by the Company in current reports 34/2023 on July 6, 2023, 35/2023 on July 14, 2023 and 37/2023 on July 31, 2023. The initiation of both trials is scheduled for later this year.

RVU120 is a selective, first-in-class dual CDK8/CDK19 kinase inhibitor that has shown signs of clinical activity in treated patients, as well as efficacy in numerous *in vitro* and *in vivo* models of hematologic malignancies and solid tumors.

Currently, two dose escalation clinical studies of RVU120 are ongoing in patients with AML/HR-MDS and solid tumors.

Expanding the clinical development in AML/HR-MDS through the initiation of Phase II clinical trials is part of the planned broad clinical development of RVU120 in multiple indications (hematology and solid tumors) and various treatment options (monotherapy and combination therapy), aiming at maximizing the potential of RVU120 and diversifying the risks associated with further clinical development.

The initiation of Phase II clinical trials of RVU120 in hematologic indications (including the RIVER-52 and RIVER-81 studies) as well as solid tumors is planned for the second half of 2023.

Fortrea is a global provider of clinical development and patient access solutions to the life sciences industry. Fortrea provides phase I-IV clinical trial management, clinical pharmacology, differentiated technology-enabled trial solutions and post-approval services.

The Agreements meet the criteria of significant agreements due to their importance for the further development of the RVU120 clinical program and constitute an element of the implementation of the Development Plans. The terms of the Agreements do not deviate from the conditions customarily accepted for this type of agreements.

Disclaimer: This English language translation has been prepared solely for the convenience of English-speaking readers. Despite all the efforts devoted to this translation, certain discrepancies, omissions or approximations may exist. In case of any differences between the Polish and the English versions, the Polish version shall prevail.

Ryvu Therapeutics S.A., its representatives and employees decline all responsibility in this regard.

Legal basis: 17.1 MAR

Representatives of the Issuer:

- Paweł Przewięźlikowski – President of the Management Board
- Kamil Sitarz – Member of the Management Board